Articles From: IoT Will Fire up the Next Generation of Engineers Says ARM and UCL to Ipsen Biopharmaceuticals to Present Further Data on Recently FDA-Approved Antitumor Therapy, Somatuline® Depot® (lanreotide), at Gastrointestinal Cancers Symposium


2015/1/21
ARM is partnering with UCL (University College London) to launch a new education kit aimed at developing students’ Internet of Things (IoT) technical skills.
Sign-up for IoT Will Fire up the Next Generation of Engineers Says ARM and UCL investment picks
2014/12/9
TAMA, Iowa, Dec.
Sign-up for Iowa Premium Beef Selects OneNeck(R) IT Solutions to Provide New Communications Platform investment picks
http://media.marketwire.com/attachments/201205/45279_iPasslogo.jpg http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1154804&ProfileId=051205&sourceType=1 REDWOOD SHORES, CA --
Sign-up for iPass Makes Significant Improvements to iPass App for Android investment picks
http://media.marketwire.com/attachments/201205/45279_iPasslogo.jpg http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1169622&ProfileId=051205&sourceType=1 REDWOOD SHORES, CA --
Sign-up for iPass Provides Mobile Carrier Melita With Global Wi-Fi Access investment picks
http://media.marketwire.com/attachments/201404/73822_ipass.jpg http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1157068&ProfileId=051205&sourceType=1 REDWOOD SHORES, CA --
Sign-up for iPass Reports Sequential OM Revenue Growth in the Third Quarter 2014 investment picks
http://media.marketwire.com/attachments/201311/200249_iPass_logo_color.jpg http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1161687&ProfileId=051205&sourceType=1 REDWOOD SHORES, CA --
Sign-up for iPass to Present at the LD Micro Conference investment picks
http://media.marketwire.com/attachments/201404/73822_ipass.jpg http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1155526&ProfileId=051205&sourceType=1 REDWOOD SHORES, CA --
Sign-up for iPass Wi-Fi Growth Map Shows 1 Public Hotspot for Every 20 People on Earth by 2018 investment picks
NORTH HOLLYWOOD, Calif., Nov.
Sign-up for IPC Continues Expanding Presence in Florida With Acquisition of Acute and Post-Acute Practice investment picks
NORTH HOLLYWOOD, Calif., Oct.
Sign-up for IPC Continues Investment in Post-Acute Market With Acquisition of Comprehensive Health Solutions investment picks
NORTH HOLLYWOOD, Calif., Nov.
Sign-up for IPC Expands Presence in Western Michigan With Acquisition of Post-Acute Practice investment picks
NORTH HOLLYWOOD, Calif., Jan.
Sign-up for IPC Healthcare to Present at J.P. Morgan Healthcare Conference investment picks
IPC The Hospitalist Company, Inc. (Nasdaq: IPCM), a leading national hospital medicine and post-acute physician group practice company, announced today that it has appointed Jennifer Miraglia to the position of Executive Director for its Chicago region.
Sign-up for IPC Names New Executive Director in Chicago investment picks
NORTH HOLLYWOOD, Calif., Oct.
Sign-up for IPC Names New General Counsel and Corporate Secretary investment picks
NORTH HOLLYWOOD, Calif., Jan.
Sign-up for IPC The Hospitalist Company Changes Name to IPC Healthcare investment picks
NORTH HOLLYWOOD, Calif., Oct.
Sign-up for IPC The Hospitalist Company Reports Third Quarter 2014 Financial Results investment picks
NORTH HOLLYWOOD, Calif., Oct.
Sign-up for IPC The Hospitalist Company to Report Third-Quarter 2014 Financial Results investment picks
NORTH HOLLYWOOD, Calif., Nov.
Sign-up for IPC The Hospitalist Company, Inc. to Participate in Upcoming Investor Conferences investment picks
NORTH HOLLYWOOD, Calif., Nov.
Sign-up for IPC The Hospitalist Company, Inc. to Present at Piper Jaffray Healthcare Conference investment picks
IPG Photonics Corporation (NASDAQ: IPGP) today reported financial results for the third quarter ended September 30, 2014.
Sign-up for IPG Photonics Reports 16% Revenue Growth for Third Quarter 2014 investment picks
IPG Photonics Corporation (NASDAQ: IPGP) today announced that management will be presenting at the 17 th Annual Needham Growth Conference on Tuesday, January 13, 2015 at 3:30 p.m. ET.
Sign-up for IPG Photonics to Present at 17th Annual Needham Growth Conference investment picks
2014/12/9
Last week's review of corporations and law firms NEW YORK , Dec.
Sign-up for IPOs and Transactions Week in Review: December 1 - 5 investment picks
Regulatory News: IPSEN (Euronext: IPN; ADR: IPSEY) and French National Center for Scientific Research (CNRS) today announced the creation of the Archi-Pex (peptide architectures and formulations) joint research and innovation lab in collaboration with the French Alternative Energies and Atomic Energy Commission (CEA) and the University of Rennes 1.
Sign-up for Ipsen and CNRS Create the "Archi-Pex" Joint Research and Innovation Lab, in Collaboration with the University of Rennes 1 and CEA investment picks
2014/11/18
Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) and the Salk Institute for Biological Studies (Salk Institute) today announced that they have agreed to renew their collaboration in medical sciences for another three years.
Sign-up for Ipsen and the Salk Institute renew their agreement for discovery research in medical sciences investment picks
Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review its supplemental Biologics License Application (sBLA) for Dysport ® (abobotulinumtoxinA) in the treatment of upper limb spasticity in adult patients.
Sign-up for Ipsen Announces FDA Acceptance of Filing for Dysport® in the Treatment of Upper Limb Spasticity in Adult Patients investment picks
Ipsen Biopharmaceuticals, Inc., an affiliate of Ipsen (Euronext: IPN; ADR: IPSEY), today announced that the U.S. Food and Drug Administration (FDA) has approved a new device to deliver Somatuline ® Depot ® (lanreotide). The device has an enhanced, prefilled, low-volume syringe that supports full-dose delivery with no reconstitution requirements.
Sign-up for Ipsen Announces FDA Approval of a New Delivery Device for Somatuline® Depot® (lanreotide) Injection investment picks
Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) today announced that the International Breast Cancer Study Group (IBCSG) presented results of the randomized phase III SOFT clinical trial at the 2014 San Antonio Breast Cancer Symposium.
Sign-up for Ipsen Announces That the International Breast Cancer Study Group (IBCSG) Presented Phase 3 Results Evaluating the Use of Ovarian Suppression to Adjuvant Treatment with Tamoxifen investment picks
Ipsen Biopharmaceuticals, Inc. , an affiliate of Ipsen (Euronext: IPN; ADR: IPSEY), today announced that Somatuline ® Depot ® (lanreotide) Injection 120 mg (referred to as Somatuline ® ) was approved by the U.S. Food and Drug Administration (FDA) for the treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) in adult patients with unresectable, well or moderately differentiated, locally advanced or metastatic disease to improve progression-free survival (PFS). “The approval of Somatuline ® for the treatment of patients living with gastrointestinal and pancreatic tumors is a major achievement for Ipsen that will provide a new therapeutic option with the potential to help many of the thousands of patients in the United States suffering from this devastating disease,” said Cynthia Schwalm, President and CEO of Ipsen
Sign-up for Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors investment picks
2015/1/13
Ipsen Biopharmaceuticals Inc. , an affiliate of Ipsen (Euronext:IPN; ADR:IPSEY) today announced three presentations of lanreotide data to be shared at the 2015 Gastrointestinal Cancers Symposium, January 15-17, 2015 in San Francisco, CA.
Sign-up for Ipsen Biopharmaceuticals to Present Further Data on Recently FDA-Approved Antitumor Therapy, Somatuline® Depot® (lanreotide), at Gastrointestinal Cancers Symposium investment picks
Go Premium!
Exclusive Premium Member Benefits
Get the best thinking of 150+ disciplined
objective, experienced analysts-dedicated to
specific industries and securities.
+2,500 Analyst Reports
Wide Moat Screener for Stocks
Medalist Screener for Funds
Premium Portfolio Manager with X-Ray & Monitor
Premium eNewsletters
Morningstar Basic Benefits (All)
Sign up now - No charge for the first 14 days
Articles From: IoT Will Fire up the Next Generation of Engineers Says ARM and UCL to Ipsen Biopharmaceuticals to Present Further Data on Recently FDA-Approved Antitumor Therapy, Somatuline® Depot® (lanreotide), at Gastrointestinal Cancers Symposium
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices |  Most Recent